DSM-Firmenich: From Dutch State Mines to a Swiss-Dutch Nutrition and Fragrance Group

dsm-firmenich is the story of a company that has changed what it sells four times in 120 years, and of a merger that moved one of the Netherlands’ oldest industrial names to Switzerland. The Dutch state created DSM to mine coal, privatised it as a chemicals producer, watched it become a vitamins and nutrition leader, and then saw it combine with a family-owned perfume maker to form a group whose legal seat is in Kaiseraugst, near Basel. This article traces the transformation, explains the merger terms, examines why the animal-nutrition business was sold and reads the 2025 and first-half 2026 results. It is part of the Netherlands Company Stories hub.

How did a Dutch coal-mining company end up making vitamins and perfume?

DSM reached vitamins and perfume through a sequence of deliberate exits, each one abandoning a business that had become commoditised. The Dutch state founded De Staatsmijnen in 1902 to exploit the coal seams of southern Limburg, and by the 1930s the company was also producing fertiliser and chemicals from coke-oven gas. The last Dutch coal mine closed in 1973; by then DSM was already a petrochemicals producer.

Privatisation followed in two steps, with the state floating 70% of the shares on the Amsterdam exchange in 1989 and selling the remainder in 1996. The company then spent the 2000s swapping commodity chemistry for specialities: it sold its petrochemicals operations to Saudi Arabia’s SABIC in 2002 and used the proceeds to buy Roche’s vitamins and fine-chemicals division in 2003 for about €1.75 billion, a deal that remains the foundation of its nutrition business today. Under Feike Sijbesma, CEO from 2007 to 2020, DSM added Martek Biosciences, a producer of algae-derived omega-3 oils, in 2011, and pushed sustainability to the centre of its investment case.

The final step out of materials came in 2022 and 2023. DSM sold its protective-materials business, built around the Dyneema fibre, to Avient for about US$1.5 billion, and its engineering-materials business to Advent International and Lanxess for about €3.85 billion. That left a company made entirely of nutrition, health and biosciences ingredients, with sales of roughly €7 billion, and a question about what to do next. The answer was Firmenich.

The company’s history is a useful counterpoint to other Dutch industrial transformations. Where Philips narrowed to health technology, a story covered in the Philips Respironics article, DSM moved along the value chain from raw materials to ingredients that end up in food, feed, supplements and cosmetics. Both ended up far from their founding purpose.

What were the terms of the Firmenich merger?

The merger, announced on 31 May 2022 and completed on 9 May 2023, was structured as a combination in which DSM shareholders received about 65.5% of the new company and the Firmenich family shareholders received about 34.5% plus a cash payment of €3.5 billion. The combined entity was incorporated in Switzerland as dsm-firmenich AG, with its registered seat in Kaiseraugst and a co-headquarters in Maastricht.

Firmenich was a very different kind of business. Founded in Geneva in 1895 as Chuit & Naef, and renamed after Fred Firmenich became majority partner, it had remained privately owned by the Firmenich family for five generations. By 2021 it had sales of CHF 4.3 billion, about 10,000 employees and a position as the world’s largest private fragrance and taste company. Its chairman, Patrick Firmenich, had led the business as CEO until 2014.

The strategic logic was that fragrance, flavour and nutrition ingredients are sold to the same customers, consumer-goods and food companies, through similar technical-sales channels, and that DSM’s biotechnology could be applied to Firmenich’s perfumery molecules. The combined company set a synergy target of about €350 million in annual Adjusted EBITDA, split between cost and revenue synergies. By the end of 2025 it reported roughly €175 million of cost synergies fully delivered and about €175 million of revenue synergies, with another €115 million of EBITDA from revenue synergies expected by 2027.

The merger also changed the leadership structure. DSM’s co-CEOs, Geraldine Matchett and Dimitri de Vreeze, initially shared the top job at the merged company; from January 2024 De Vreeze became sole CEO. Thomas Leysen, the Belgian industrialist who chaired DSM, chaired the merged board until his retirement; shareholders elected Richard Ridinger as his successor on 19 October 2026.

Why did the headquarters move to Switzerland?

The legal headquarters moved to Switzerland because the merger was structured as a Swiss company absorbing a Dutch one, a choice driven by the Firmenich family’s requirements and by the lower effective tax and simpler governance that a Swiss domicile offered. DSM’s old headquarters in Heerlen was replaced by a new building in Maastricht, opened by Queen Máxima in May 2024, which the company describes as one of its two headquarters.

For the Netherlands the symbolism was awkward. DSM had been a state-owned company for most of its life and was one of the founding members of the AEX index. Its shares still trade in Amsterdam under the ticker DSFIR and the company remains an AEX constituent, but its ISIN is Swiss, its board meets under Swiss law and its dividends are subject to Swiss withholding tax rules, which is why the 2025 dividend of €2.50 per share was split into a €1.64 tranche paid from capital-contribution reserves without withholding tax and a €0.86 tranche subject to the 35% Swiss rate. In May 2026 the company added a listing on the SIX Swiss Exchange, giving Swiss investors a home-market quote.

The move fits a pattern explored elsewhere in this hub. Shell shifted its headquarters and tax residence to London in 2022, Unilever unified in London in 2020, and other groups have cited the Dutch dividend-withholding tax and a less predictable political climate as reasons to leave, a debate covered in the headquarters-exodus article. dsm-firmenich is different in that it kept a large operational presence, including research in Delft and manufacturing in Limburg, but the trend of Dutch icons choosing foreign domiciles is unmistakable.

What does dsm-firmenich actually sell?

dsm-firmenich sells ingredients that consumers never see but encounter every day: fragrance compounds for perfumes and detergents, flavours and texturants for food and drink, vitamins and specialised nutrients for supplements, infant formula and pharmaceuticals. Since the animal-nutrition business was classified as discontinued, it reports three business units.

Perfumery & Beauty is the largest, with 2025 sales of €3,760 million and an Adjusted EBITDA margin of 21.7%. It combines Firmenich’s fine-fragrance and consumer-fragrance creation with DSM’s aroma ingredients and personal-care actives, and it is the business most exposed to luxury-goods demand; in October 2026 the company opened a fine-fragrance flagship in Chelsea, New York, to court perfume brands.

Taste, Texture & Health, with 2025 sales of €3,146 million and a 20.6% margin, serves food and beverage manufacturers with flavours, sweeteners, cultures, enzymes and hydrocolloids. Health, Nutrition & Care, at €2,102 million and a 19.4% margin, sells vitamins, lipids, probiotics and pharma-grade ingredients to supplement makers, infant-formula producers and drug companies, and is the unit that most directly descends from the 2003 Roche acquisition.

Combined, the continuing businesses generated €9,034 million of sales in 2025, flat in reported terms but up 3% organically, and Adjusted EBITDA of €1,772 million. Nearly 30,000 people work across more than 300 sites in over 60 countries. The nutrition link to Dutch agriculture, through feed ingredients for the dairy and livestock sectors, connects this story to the FrieslandCampina article.

Why was Animal Nutrition & Health sold, and on what terms?

Animal Nutrition & Health was sold because its economics no longer fitted a consumer-ingredients group. The business sells vitamins, carotenoids, enzymes and premixes to feed producers, and its profits swing with the global vitamin price cycle. A collapse in vitamin prices in 2023 dragged the unit’s margins into single digits and made the whole group look more cyclical than its fragrance and flavour peers.

The divestment came in two parts. In February 2025 the company agreed to sell its stake in the Feed Enzyme Alliance, a long-standing partnership with Novozymes (now Novonesis), to Novonesis for €1.5 billion. Then on 9 February 2026 it announced the sale of the remaining ANH business to CVC Capital Partners at an enterprise value of about €2.2 billion, including an earn-out of up to €0.5 billion. dsm-firmenich retains a 20% equity stake in each of the two standalone companies CVC is creating, an “Essential Products” company and a “Solutions” company, both to be based in Kaiseraugst, and expects to realise that value when CVC exits.

The company says the two deals together value ANH at €3.7 billion, or about ten times normalised Adjusted EBITDA, against seven times for the CVC transaction alone. Expected proceeds after closing are about €1.2 billion, of which roughly €0.6 billion is net cash, about €0.5 billion is debt and liabilities transferred to the new companies and €0.1 billion is a vendor loan note. Some €0.2 billion of cash taxes, transaction and separation costs will fall in 2026, and dsm-firmenich is providing a loan facility of up to €450 million plus up to €115 million of liquidity support to the Essential Products company. Closing is expected around the end of 2026, subject to regulatory approvals and employee consultations.

What do the 2025 results say about the merged company?

The 2025 results show a profitable core and an expensive exit. Continuing operations delivered sales of €9,034 million, organic growth of 3%, Adjusted EBITDA of €1,772 million and a margin of 19.6%, up 30 basis points. Core adjusted net profit was €887 million, or €3.31 per share, and core adjusted return on capital employed 11.1%.

The total-group picture was worse. Including the discontinued animal-nutrition business, sales were €12,521 million, down 2%, and the group booked a net loss of €1,039 million, against a €280 million profit in 2024, because of a non-cash impairment of about €1.9 billion before tax on ANH ahead of the sale. Net debt rose to €3,301 million, partly because the company spent about €1 billion buying back shares during 2025, a programme completed in December.

Operating working capital crept up to 28.8% of sales from 27.3%, and adjusted gross operating free cash flow fell to 10.4% of sales from 12.1%, which is why cash conversion featured prominently in De Vreeze’s commentary. He described the ANH sale as the final step in the strategic roadmap toward a consumer-focused nutrition, health and beauty company and said the portfolio had held up in a tougher macroeconomic second half.

The company’s medium-term ambitions, set at its June 2024 capital-markets day and reiterated in early 2026, are organic sales growth of 5% to 7%, an Adjusted EBITDA margin of 22% to 23% and cash conversion above 10% of sales. On every measure, 2025 fell short, and the shares have traded accordingly; the group now sells for a discount to Swiss peer Givaudan and to Symrise that reflects doubts about whether the merger integration can close the gap.

How is the first half of 2026 going?

The first half of 2026 showed better growth and a slightly lower margin. Sales from continuing operations were €4,664 million, up 5% like for like, with the second quarter accelerating to 6%. Adjusted EBITDA was €900 million, up 7% like for like but down slightly in reported terms because of currency effects, for a margin of 19.3% against 19.5% a year earlier. Core adjusted earnings per share rose 14% to €1.84, helped by the smaller share count.

Perfumery & Beauty led with 7% like-for-like growth and a 21.8% margin; Taste, Texture & Health grew 4% with a 19.6% margin; Health, Nutrition & Care grew 4% in sales but 15% in EBITDA, taking its margin to 19.9%. Net debt stood at €4,424 million at the end of June, inflated by a €540 million share buyback that started in March and was completed on 1 October 2026, and by the reclassification of ANH debt.

Management kept the 2026 guidance of 2% to 4% like-for-like growth, now expected at the upper end, an Adjusted EBITDA margin of around 20% and adjusted gross operating free cash flow of 11% to 12% of sales. It also announced a restructuring programme that will cut about 1,000 positions over 18 to 24 months, subject to works-council consultation, at an exceptional cost of about €100 million and with expected annual savings of €100 million, equivalent to roughly one percentage point of margin by 2027. The next data point is the third-quarter trading update on 4 November 2026.

What are the risks for dsm-firmenich from here?

The main risks are integration fatigue, currency and the possibility that the ANH sale does not close on the planned terms. Three years after the merger, the company is still running synergy programmes, a restructuring and a separation at the same time, and each draws on the same management bandwidth.

Currency is the most visible headwind in the numbers. The company reports in euros but earns a large share of its revenue in US dollars and emerging-market currencies, and the 2026 margin was reduced by about 70 basis points in the second quarter by foreign-exchange effects. A sustained weak dollar would make the 22% to 23% margin target harder to reach even if the operating plan succeeds.

The ANH transaction carries its own risks. Closing depends on regulatory approvals in several jurisdictions and on completing the carve-out of two standalone companies with about 8,000 employees. dsm-firmenich is lending up to €450 million to one of them and keeping 20% of both, so a weak vitamin market after closing would feed back into its own results through the equity stakes and the earn-out. The first quarter of 2026 gave a taste: ANH’s quarterly sales fell 23% to €722 million and its Adjusted EBITDA collapsed to €23 million, though the company expects improvement after recent vitamin price increases.

What can founders and investors learn from DSM and dsm-firmenich?

The DSM story offers lessons on portfolio management that apply well beyond chemicals.

First, reinvention is a repeatable skill, not a one-off event. DSM exited coal, then bulk chemicals, then materials, each time before the business became a liability and each time redeploying capital into higher-margin activities. The pattern required a board willing to sell profitable businesses at the top rather than the bottom of their cycle, a discipline most companies lack.

Second, mergers of equals are rarely equal. The Firmenich family’s one-third stake, the Swiss domicile and the retention of Firmenich’s fragrance culture suggest that DSM, the larger partner by revenue, ceded a great deal to get the deal done. Whether that was wise depends on the synergies, which at €350 million against a combined EBITDA of about €2 billion are meaningful but not transformational. Investors should read merger announcements for who controls the domicile, the chair and the capital-allocation policy, not just the exchange ratio.

Third, sum-of-the-parts logic cuts both ways. Selling ANH removes a cyclical drag and should lift the group multiple, but it also removes €3.5 billion of annual sales and leaves a smaller company more exposed to consumer-spending swings in fragrance and flavour. Specialisation is a bet on the remaining businesses, and the 2026 restructuring is an admission that the cost base has to shrink to match.

Fourth, domicile is a strategic choice with consequences for stakeholders. The Netherlands lost a founding AEX member to Switzerland in all but listing. For founders considering where to incorporate, and for policymakers wondering why companies leave, dsm-firmenich is a reminder that tax, governance and the preferences of anchor shareholders can outweigh a century of national history. Readers interested in how other Dutch groups handled the same question can compare the Unilever headquarters story and the biotech firms profiled in the Dutch-Belgian biotech corridor article.

Frequently Asked Questions